Tue, 02 Dec 2014 06:16:00 GMT ~ 1:16 am Medivation's XTANDI now approved in Europe for the treatment of men with metastatic castration-resistant prostate cancer who are chemotherapy-na ve
Tue, 02 Dec 2014 00:01:00 GMT ~ XTANDI™ (enzalutamide) Now Approved in Europe for the Treatment of Men with Metastatic Castration-Resistant Prostate Cancer Who Are Chemotherapy-Naïve
Tue, 25 Nov 2014 21:34:03 GMT ~ Joseph Lobacki to Become Medivation's Chief Commercial Officer
[at noodls] - SAN FRANCISCO, CA -- (Marketwired) -- 11/25/14 -- Medivation, Inc. (NASDAQ: MDVN) today announced that Joseph Lobacki will join the company as chief commercial officer on December 8, 2014. In this position, ...
Link: http://www.otcmarkets.com/stock/MDVN/company-info Ticker: $MDVN OTC Market Place: Not Available CIK code: 0001011835 Company name: Medivation, Inc. Incorporated In: DE, USA
$MDVN share structure
## source: otcmarkets.com
Market Value: $8,794,097,618 a/o Dec 02, 2014 Shares Outstanding: 77,624,659 a/o Oct 31, 2014 Float: Not Available Authorized Shares: Not Available Par Value: 0.01 $MDVN extra dd links